SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Isaac Newton Synthetic CCD

PatientIsaac Newton
Date of birth1976-01-04
IdentifiersMRN HR-EN011-SYN; SSN (made up) 000-11-6840
Document date2026-11-01
AuthorRupert Okonkwo-Fairbanks, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

Primary care visit for a year of poor sleep and appetite, two weeks of near-sleeplessness, and suspicious thoughts about friends, in a researcher who heats mercury and other metals. Concerns: He has barely slept for two weeks, eats little, and feels he has lost his former steadiness of mind; He wrote angry letters to friends he now thinks he wronged, and wants to make amends; He asks whether the metals in his laboratory have poisoned him. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Sertraline 50 mg oral tablet, one tablet by mouth each morningOne tablet by mouth each morningOral route2026-10-08activeS
Acetaminophen 500 mg oral tablet, one or two tablets by mouth every 6 hours as needed for aches or fever, no more than 3 g a dayOne or two tablets every 6 hours as needed; no more than six tablets a dayOral route2026-10-15 to 2026-10-22completedS

Immunizations

DateVaccineStatusEvidence
2020-06-15Tdap vaccinecompletedS
2019-03-04Hepatitis B vaccine, two-dose adult series completedcompletedS
2026-10-22Influenza vaccine, 2026-2027 seasoncompletedS
2026-10-22Pneumococcal conjugate vaccine PCV20completedS
2026-10-22Recombinant zoster vaccine, dose 1 of 2completedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
Autumn 1692 (Julian)Loss of appetite and want of sleep from the previous autumn, continuing for nearly a year, by his biographer's accountD (CLM-0004)

Family History

RelativeConditionAge at deathEvidence
fatherDied before the patient was born; cause not recorded in the cited sourceD (CLM-0001)

Health Concerns

ConcernStatusEvidence
He has barely slept for two weeks, eats little, and feels he has lost his former steadiness of mindactiveS
He wrote angry letters to friends he now thinks he wronged, and wants to make amendsactiveS
He asks whether the metals in his laboratory have poisoned himactiveS

Assessment

Most recent measures: Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 14 on 2026-10-29; Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 7 on 2026-10-29; Total score [MoCA] 27 on 2026-09-28; Hemoglobin [Mass/volume] in Blood 14.6 on 2026-09-28; MCV [Entitic mean volume] in Red Blood Cells by Automated count 91 on 2026-09-28; Leukocytes [#/volume] in Blood by Automated count 6.1 on 2026-09-28; Platelets [#/volume] in Blood by Automated count 242 on 2026-09-28; Sodium [Moles/volume] in Serum or Plasma 140 on 2026-09-28; Potassium [Moles/volume] in Serum or Plasma 4.3 on 2026-09-28; Urea nitrogen [Mass/volume] in Serum or Plasma 15 on 2026-09-28; Creatinine [Mass/volume] in Serum or Plasma 0.92 on 2026-09-28; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 101 on 2026-09-28; Glucose [Mass/volume] in Serum or Plasma 88 on 2026-09-28; Calcium [Mass/volume] in Serum or Plasma 9.5 on 2026-09-28; Albumin [Mass/volume] in Serum or Plasma 4.2 on 2026-09-28; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 24 on 2026-09-28; Thyrotropin [Units/volume] in Serum or Plasma 1.9 on 2026-09-28; Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma 455 on 2026-09-28; Albumin/Creatinine [Mass Ratio] in Urine 9 on 2026-09-28; Mercury [Mass/volume] in Blood 3.1 on 2026-10-29; Lead [Mass/volume] in Blood 2.4 on 2026-09-28; Mercury [Mass/volume] in 24 hour Urine 31 on 2026-10-29; Mercury/Creatinine [Mass Ratio] in 24 hour Urine 27 on 2026-10-29; Cholesterol [Mass/volume] in Serum or Plasma 176 on 2026-10-22; Cholesterol in HDL [Mass/volume] in Serum or Plasma 61 on 2026-10-22; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 98 on 2026-10-22; Triglyceride [Mass/volume] in Serum or Plasma 86 on 2026-10-22 [S]

Strengths and supports: engagement in care [S]

Problems

ProblemClinical statusVerificationCodeProvenance
A year of poor sleep and poor appetite with 4 kg weight loss, two weeks of near-total sleeplessness, low spirits, and suspicious thoughts that colleagues and friends were plotting against him, now partly doubted; under evaluation for depression, a toxic cause, and other medical causesresolvedconfirmed R45.89S — Synthetic presenting concern echoing the poor sleep, poor appetite, distress, and retracted suspicions documented in his letters of September 1693; superseded by the diagnoses at the second visit.
Occupational exposure to elemental and inorganic mercury, with lesser exposure to lead, antimony, and arsenic compounds, from heating metals in an unventilated private laboratoryactiveconfirmed Z57.5S — Synthetic modern exposure echoing his documented chemical and alchemical work with metals, including mercury; no level of historical exposure is asserted.
Major depressive disorder, single episode, severe, without psychotic features (PHQ-9 20 at intake): a year of poor sleep and appetite with weight loss, low mood, poor concentration, and suspicious ideas held with partial insight; medical causes excluded; the contribution of low-level mercury exposure is uncertainactiveconfirmed F32.2S — Synthetic modern diagnosis. His sleeplessness, poor appetite, distress, and melancholy in 1693 are documented (D); calling them major depression is a modern reading, and mercury poisoning and other explanations proposed later are disputed (R).
Chronic insomnia comorbid with depression: sleep onset and maintenance difficulty for a year, with two weeks of near-total sleeplessness before intakeactiveconfirmed G47.00S — Synthetic diagnosis echoing his documented sleeplessness.
Raised urine mercury from occupational exposure (24-hour urine 46 ug/L, 41 ug/g creatinine; blood 9.4 ug/L) without tremor, gingivitis, erethism, neuropathy, or kidney injury; below the levels linked to overt toxicityactiveconfirmed R82.6S — Synthetic result echoing his documented work with mercury; it does not assert that he was poisoned (see CLM-0011, R, disputed).
Acute viral upper respiratory infection (common cold) with a low-grade fever, sore throat, and cough, a week after starting sertraline; resolvedresolvedconfirmed J06.9S — Synthetic intercurrent illness at an unscheduled visit; it echoes, without asserting, his documented mention of a distemper that was epidemical that summer (CLM-0008).

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-09-28Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]20{score}S
2026-09-28Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]11{score}S
2026-09-28Total score [MoCA]27{score}S
2026-09-28Hemoglobin [Mass/volume] in Blood14.6g/dL13.2-16.6 g/dLNormalS
2026-09-28MCV [Entitic mean volume] in Red Blood Cells by Automated count91fL80-100 fLNormalS
2026-09-28Leukocytes [#/volume] in Blood by Automated count6.110*3/uL3.4-9.6 10*3/uLNormalS
2026-09-28Platelets [#/volume] in Blood by Automated count24210*3/uL150-400 10*3/uLNormalS
2026-09-28Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
2026-09-28Potassium [Moles/volume] in Serum or Plasma4.3mmol/L3.5-5.1 mmol/LNormalS
2026-09-28Urea nitrogen [Mass/volume] in Serum or Plasma15mg/dL8-24 mg/dLNormalS
2026-09-28Creatinine [Mass/volume] in Serum or Plasma0.92mg/dL0.74-1.35 mg/dLNormalS
2026-09-28Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M101mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-09-28Glucose [Mass/volume] in Serum or Plasma88mg/dL70-99 mg/dLNormalS
2026-09-28Calcium [Mass/volume] in Serum or Plasma9.5mg/dL8.6-10.3 mg/dLNormalS
2026-09-28Albumin [Mass/volume] in Serum or Plasma4.2g/dL3.5-5 g/dLNormalS
2026-09-28Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma24U/L7-55 U/LNormalS
2026-09-28Thyrotropin [Units/volume] in Serum or Plasma1.9m[IU]/L0.4-4 mIU/LNormalS
2026-09-28Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma455pg/mL232-1245 pg/mLNormalS
2026-09-28Albumin/Creatinine [Mass Ratio] in Urine9mg/g{creat}<=30 mg/g{creat}NormalS
2026-09-28Mercury [Mass/volume] in Blood9.4ug/L95th percentile of US adults below 5 ug/L (ATSDR); 50 ug/L or more is the threshold for symptoms of toxicityHighS
2026-09-28Lead [Mass/volume] in Blood2.4ug/dLBelow 3.5 ug/dL (CDC blood lead reference value)NormalS
2026-09-28Mercury [Mass/volume] in 24 hour Urine46ug/LBackground below 2 ug/L (95th percentile of adults); below 20 ug/L not associated with effects (ATSDR)HighS
2026-09-28Mercury/Creatinine [Mass Ratio] in 24 hour Urine41ug/g{creat}Occupational biological exposure index 20 ug/g creatinineHighS
2026-10-08Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]19{score}S
2026-10-22Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]16{score}S
2026-10-22Cholesterol [Mass/volume] in Serum or Plasma176mg/dL<=199 mg/dLNormalS
2026-10-22Cholesterol in HDL [Mass/volume] in Serum or Plasma61mg/dL>=40 mg/dLNormalS
2026-10-22Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation98mg/dL<=129 mg/dLNormalS
2026-10-22Triglyceride [Mass/volume] in Serum or Plasma86mg/dL<=149 mg/dLNormalS
2026-10-29Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]14{score}S
2026-10-29Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]7{score}S
2026-10-29Mercury [Mass/volume] in Blood3.1ug/L95th percentile of US adults below 5 ug/L (ATSDR); 50 ug/L or more is the threshold for symptoms of toxicityNormalS
2026-10-29Mercury [Mass/volume] in 24 hour Urine31ug/LBackground below 2 ug/L (95th percentile of adults); below 20 ug/L not associated with effects (ATSDR)HighS
2026-10-29Mercury/Creatinine [Mass Ratio] in 24 hour Urine27ug/g{creat}Occupational biological exposure index 20 ug/g creatinineHighS

Social History

Vital Signs

DateMeasureValueUnitProvenance
2026-09-28Body height170cmS
2026-09-28Body weight64kgS
2026-09-28Body mass index (BMI) [Ratio]22.1kg/m2S
2026-09-28Systolic blood pressure124mm[Hg]S
2026-09-28Diastolic blood pressure78mm[Hg]S
2026-09-28Heart rate84/minS
2026-09-28Respiratory rate14/minS
2026-09-28Body temperature36.7CelS
2026-09-28Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-10-08Body height170cmS
2026-10-08Body weight63.8kgS
2026-10-08Body mass index (BMI) [Ratio]22.1kg/m2S
2026-10-08Systolic blood pressure122mm[Hg]S
2026-10-08Diastolic blood pressure76mm[Hg]S
2026-10-08Heart rate80/minS
2026-10-08Respiratory rate14/minS
2026-10-08Body temperature36.6CelS
2026-10-08Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-10-15Body height170cmS
2026-10-15Body weight63.9kgS
2026-10-15Body mass index (BMI) [Ratio]22.1kg/m2S
2026-10-15Systolic blood pressure120mm[Hg]S
2026-10-15Diastolic blood pressure74mm[Hg]S
2026-10-15Heart rate90/minS
2026-10-15Respiratory rate16/minS
2026-10-15Body temperature37.8CelS
2026-10-15Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-10-22Body height170cmS
2026-10-22Body weight64.3kgS
2026-10-22Body mass index (BMI) [Ratio]22.2kg/m2S
2026-10-22Systolic blood pressure120mm[Hg]S
2026-10-22Diastolic blood pressure76mm[Hg]S
2026-10-22Heart rate76/minS
2026-10-22Respiratory rate14/minS
2026-10-22Body temperature36.6CelS
2026-10-22Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-10-29Body height170cmS
2026-10-29Body weight64.8kgS
2026-10-29Body mass index (BMI) [Ratio]22.4kg/m2S
2026-10-29Systolic blood pressure118mm[Hg]S
2026-10-29Diastolic blood pressure74mm[Hg]S
2026-10-29Heart rate72/minS
2026-10-29Respiratory rate14/minS
2026-10-29Body temperature36.6CelS
2026-10-29Oxygen saturation in Arterial blood by Pulse oximetry99%S

Encounters

DatePurposeStatusProvenance
2026-09-28Primary care visit for a year of poor sleep and appetite, two weeks of near-sleeplessness, and suspicious thoughts about friends, in a researcher who heats mercury and other metalsfinishedS
2026-10-08Ten-day review of metal and laboratory results, diagnosis, start of treatment, and occupational and environmental medicine consultationfinishedS
2026-10-29Three-week depression and exposure follow-up with a repeat 24-hour urine mercuryfinishedS
2026-10-15Same-day sick visit for a cold one week after starting sertralinefinishedS
2026-10-22Preventive health visit at 50finishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Workup for medical and toxic causes: blood count, metabolic panel, TSH, vitamin B12, MoCA, urine albumin-to-creatinine ratio and dipstick protein, blood mercury, 24-hour urine mercury with creatinine, and blood lead; examination for tremor, gingivitis, stomatitis, and neuropathy; no provoked (chelator-challenge) urine test and no broad metal screencompletedGL-CMID-2026, GL-APA-DEP-2019, GL-MDD-2022, GL-ATSDR-HG-2018, GL-NIOSH-HG, GL-ACMT-2010, GL-ACMT-CHEL-2013S
Removal from exposure now: stop all heating of metals, close the laboratory, and do not sleep in the adjoining rooms until they are checked; the university environmental health and safety office to measure mercury vapor, decontaminate, and remove the mercury and arsenic compoundscompletedGL-ATSDR-HG-2018, GL-NIOSH-HG, GL-ACMT-2010, GL-ACMT-CHEL-2013S
Suicide and violence risk assessment with a safety plan: warning signs, coping steps, people to contact, the clinic number, and the 988 Suicide & Crisis Lifeline; toxic chemicals out of reach; safety reviewed at every visitcompletedGL-SUICIDE-2024, GL-CMID-2026S
Occupational and environmental medicine (medical toxicology) consultation on the meaning of the mercury results, chelation, the workplace hazard assessment, and a safe return to laboratory workcompletedGL-ATSDR-HG-2018, GL-NIOSH-HG, GL-ACMT-2010, GL-ACMT-CHEL-2013S
Sleep: cognitive behavioral therapy for insomnia (a fixed rising time, a sleep window, out of bed after 20 minutes awake, no dozing in the evening chair, no night work); no hypnotics or sedating antihistaminescompletedGL-ACP-INSOMNIA-2016S
Shared decision on depression treatment: sertraline 50 mg each morning with weekly cognitive behavioral therapy; PHQ-9 at every visit; an increase if the response is under 50 percent after six to eight weeks; continue for at least six to twelve months after remissioncompletedGL-CMID-2026, GL-APA-DEP-2019, GL-MDD-2022, GL-DSM5TR-2022S
Collaborative care: the clinic's psychiatrist reviews his PHQ-9, safety, and medicine each week with the care manager, and sees him in person if psychotic features, suicidal thoughts, or thoughts of harming others appear, or if he does not respondcompletedGL-CMID-2026, GL-APA-DEP-2019, GL-MDD-2022S
Exposure follow-up: repeat 24-hour urine mercury and blood mercury four to six weeks after removal and again at three months; creatinine and urine albumin-to-creatinine ratio at three months; return to laboratory work only with a fume hood, a mercury spill kit, no food at the bench, and urine mercury below the biological exposure indexcompletedGL-ATSDR-HG-2018, GL-NIOSH-HG, GL-ACMT-2010, GL-ACMT-CHEL-2013S
Nutrition: three regular meals a day, weight at every visitcompletedGL-CMID-2026, GL-APA-DEP-2019, GL-MDD-2022S

Goals

GoalTargetStatusOutcomeProvenance
Toxic and other medical causes assessed by the second visit2026-10-08completedBlood count, metabolic panel, TSH, vitamin B12, kidney tests, blood lead, and MoCA normal; blood and urine mercury raised from his work, below levels linked to overt toxicityS
No further exposure to mercury and other metals until the laboratory is made safe2027-01-31activeLaboratory closed since intake; urine mercury fallingS
Response (PHQ-9 down by at least 50 percent) by eight to twelve weeks of treatment, then remission (PHQ-9 below 5)2026-12-31activePHQ-9 14 after three weeks of sertraline, 30 percent below baselineS
No suicidal thoughts and no thoughts of harming others2026-12-31activeNone at any visitS
At least six hours of sleep most nights without hypnotics2026-12-31activeAbout five and a half hours by the third chronic-care visitS

Functional Status

Mental Status

Structured synthetic safety assessment on 2026-09-28: current ideation absent, intent absent, plan absent. No suicidal ideation, intent, plan, or behavior (C-SSRS screen negative; PHQ-9 item 9 scored 0). No thoughts or intent of harming others; an angry remark about a friend is regretted, with no history of violence. Severe insomnia and depressive symptoms raise risk, so: outpatient care with a safety plan, the 988 Suicide & Crisis Lifeline and the clinic number, the laboratory closed today and its mercury and arsenic compounds to be removed by the university safety office, and review at every visit [S]